Vastag, B. US aims to tighten rules on direct-to-consumer drug ads. Nat. Biotechnol.
25, 267–267 (2007).
Food and Drug Administration Regulatory Modernization Act of 1997, H.R. 1411, 105th Cong., 1st Sess. (1997); https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm
Mogull, S. A. Chronology of direct-to-consumer advertising regulation in the United States. Am. Med. Writ. Assoc. J. 23, 106–109 (2008).
Pines, W. L. A history and perspective on direct-to-consumer promotion. Food Drug Law J.
54, 489–518 (1999).
Mintzes, B. Direct to consumer advertising is medicalising normal human experience. BMJ
324, 908–911 (2002).
Saul, S. Senate leader calls for limits on drug ads. The New York Times Politics (2 July 2005).
Kahneman, D. & Tversky, A. On the psychology of prediction. Psychol. Rev.
80, 237–251 (1973).
Nisbett, R. E., Zukier, H. & Lemley, R. E. The dilution effect: nondiagnostic information weakens the implications of diagnostic information. Cognit. Psychol.
13, 248–277 (1981).
Zukier, H. Situational determinants of behavior. Soc. Res.
49, 1073–1091 (1982).
Zukier, H. & Jennings, D. L. Nondiagnosticity and typicality effects in prediction. Soc. Cogn.
2, 187–198 (1984).
Meyvis, T. & Janiszewski, C. Consumers’ beliefs about product benefits: the effect of obviously irrelevant product information. J. Consum. Res.
28, 618–635 (2002).
Troutman, C. M. & Shanteau, J. Inferences based on nondiagnostic information. Organ. Behav. Hum. Perform.
19, 43–55 (1977).
Anderson, N. H. Integration theory and attitude change. Psychol. Rev.
78, 171–206 (1971).
Anderson, N. H. Application of an additive model to impression formation. Science
138, 817–818 (1962).
Biegler, P. & Vargas, P. Ban the sunset? Nonpropositional content and regulation of pharmaceutical advertising. Am. J. Bioeth.
13, 3–13 (2013).
Petty, R. E. & Cacioppo, J. T. Communication and Persuasion 1–24 (Springer, New York, 1986); https://doi.org/10.1007/978-1-4612-4964-1_1
Zhao, X., Lynch, J. G. & Chen, Q. Reconsidering Baron and Kenny: myths and truths about mediation analysis. J. Consum. Res.
37, 197–206 (2010).
MacKinnon, D. P., Krull, J. L. & Lockwood, C. M. Equivalence of the mediation, confounding and suppression effect. Prev. Sci.
1, 173–181 (2000).
Schwartz, L. M. & Woloshin, S. The drug facts box: improving the communication of prescription drug information. Proc. Natl Acad. Sci. USA
110, 14069–14074 (2013).
Aikin, K. J., O’Donoghue, A. C., Swasy, J. L. & Sullivan, H. W. Randomized trial of risk information formats in direct-to-consumer prescription drug advertisements. Med. Decis. Mak.
31, E23–E33 (2011).
Deese, J. & Kaufman, R. A. Serial effects in recall of unorganized and sequentially organized verbal material. J. Exp. Psychol.
54, 180–187 (1957).
Spencer, S. J., Zanna, M. P. & Fong, G. T. Establishing a causal chain: why experiments are often more effective than mediational analyses in examining psychological processes. J. Pers. Soc. Psychol.
89, 845–851 (2005).
Relations, A. M. AMA calls for ban on direct to consumer advertising of prescription drugs and medical devices. American Medical Association (17 November 2015); http://www.ama-assn.org/ama/pub/news/news/2015/2015-11-17-ban-consumer-prescription-drug-advertising.page
Thaler, R. H. & Sunstein, C. R. Libertarian paternalism. Am. Econ. Rev.
93, 175–179 (2003).
Daft, R. L. & Lengel, R. H. organizational information requirements, media richness and structural design. Manag. Sci.
32, 554–571 (1986).